# A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)

> **NCT07016802** · PHASE1 · RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 64 (estimated)

## Conditions studied

- Safety
- Tolerability
- Adult Growth Hormone Deficiency

## Interventions

- **DRUG:** GenSci134
- **DRUG:** Placebo
- **DRUG:** Recombinant Human Growth Hormone Injection (Norditropin®)

## Key facts

- **NCT ID:** NCT07016802
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-09
- **Primary completion:** 2026-11-25
- **Final completion:** 2026-11-25
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07016802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07016802, "A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07016802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*